Novel Agent May Benefit Men with CRPC

Share this content:


Cabozantinib may help treat metastatic castration-resistant prostate cancer and associated pain (CRPC). John Schieszer has the story in today's Medical Minute.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters